Novo Nordisk Wants to Sell a Weight-Loss Pill to 300 Million People

That's a reasonable bet, but it's also a bet against time. Every month without an approved oral product in China is a month where competitors dig in.

The Race Has Already Started

And the competitors aren't waiting around.

Eli Lilly has already filed its oral GLP-1 obesity drug, orforglipron, with Chinese regulators. Multiple reports frame Novo's move as an attempt to "catch up with Eli Lilly" in oral formulations. In an indirect comparison across trials (called ORION), oral Wegovy showed about 3.2 percentage points more weight loss than orforglipron, with lower rates of patients quitting due to side effects. But indirect comparisons are tricky. No head-to-head trial exists yet.

Then there are the local players, and they're not messing around. Innovent Biologics launched Xinermei (mazdutide), the first domestically developed obesity drug, in 2025. It's a dual GLP-1/GCGR agonist, a different mechanism than semaglutide, and analysts at Morningstar project it could hit peak sales of roughly 3.5 billion yuan (about $490 million) by 2029.

Pfizer is in the mix too, though by a different route. After shutting down its own GLP-1 program over liver safety concerns, Pfizer struck a deal with Sciwind Biosciences in February 2026 worth up to $495 million to commercialize Sciwind's GLP-1 therapy in China. It's a latecomer strategy, but Pfizer's commercial muscle shouldn't be underestimated.

All told, there are reportedly more than 56 GLP-1 and related incretin candidates in development across China. This isn't a two-horse race. It's a stampede.

Novo's China Playbook

Novo isn't just filing paperwork. It's building infrastructure.

The company announced a roughly $556 million expansion of its sterile-preparations facility in Tianjin, a clear signal that it plans to manufacture at scale locally rather than ship everything from Denmark. That matters in China, where regulators and payers increasingly favor companies with domestic production commitments.

The broader strategy is layered: injectable Wegovy for patients willing to use a needle today, the oral pill for the much larger group that isn't, and manufacturing capacity to serve both at volume. Think of it like a restaurant chain that starts with dine-in, then adds delivery. Same food, bigger audience.

Commercially, Novo has been targeting self-paying patients so far. But the real unlock would be commercial insurance coverage or inclusion on reimbursement lists, which could push volume dramatically higher. GLP-1 sales through digital channels like Alibaba and JD.com already hit about 1.4 billion yuan (roughly $207 million) in Q1 alone, according to Jefferies estimates. China's obesity market is going digital fast.

What Wall Street Thinks

Analysts are cautiously optimistic. Berenberg raised its price target on Novo's Copenhagen shares from 300 to 325 Danish kroner, keeping a Buy rating, and specifically cited the oral obesity pill's early reception as a catalyst. The China filing was expected, so it's not moving the needle dramatically on near-term earnings. But it reinforces the longer story: oral GLP-1s can extend Novo's growth runway for years.

The consensus view treats this as a "strategically meaningful, multi-year upside" event rather than a one-quarter firework. Investors are watching three things: how fast can Novo get approved, how broad will the label be, and can it build market share before generics arrive?

The Bottom Line

Novo Nordisk is racing to sell a weight-loss pill to a country where the obesity epidemic doubled in two decades and over 300 million people could eventually need treatment. The opportunity is enormous. So is the competition.

The semaglutide patent has already expired. Eli Lilly filed first. Local companies are launching their own drugs. Generics are on the horizon. If Novo executes well (files fast, gets approved, scales production, wins patients), oral Wegovy in China could become one of the biggest commercial opportunities in pharma. If it stumbles, those 300 million patients will have plenty of other options.

The filing hasn't happened yet. But the race is already in full sprint.

Big Pharma Is Spending $300 Billion to Avoid a Single Tax

The Trump administration threatened 100% tariffs on imported branded drugs. Pharma's response? Over $300 billion in pledged U.S. manufacturing investments, a wave of direct-to-consumer sales channels, and the biggest reshoring scramble the industry has ever seen.